Építés alatt – nem éles oldal
Belépés
Leállítva1/2. fázis

Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer

A legfontosabb adatok

Ki végzi
Henan Cancer Hospital
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Leállítva
Fázis
1/2. fázis
Résztvevők
46 fő vett részt
Kezdés
2021. dec. 8.
Befejezés
2024. júl. 3.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Famitinib
  • SHR6390
  • Fulvestrant
A regiszteradat frissítve
2024. december 17.
Miért állt le
Investigators' decision

Ki vehet részt

Életkor
18 év – 75 év
Nem
Csak nők
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 21 feltétel megnézéseKevesebb

Ki vehet részt

  • Local recurrent or metastatic breast cancer unsuitable for chemotherapy, confirmed histologically
  • HR-positive, HER2- negative breast cancer(according to 2018 ASCO/CAP HER2 test guideline)
  • Ib: Patients who received no more than 2 line of chemotherapy in advanced setting were recruited; II: Patients who had not received any chemotherapy and no more than 1 line of endocrine therapy
  • 18-75 years old
  • Eastern Cooperative Oncology Group (ECOG) performance status 0~1
  • life expectancy is not less than 12 weeks
  • at least one measurable lesion according to RECIST 1.1
  • Absolute neutrophil count (ANC) ≥ 1.5×10\^9/L, Platelets ≥90×10\^9/L, Hemoglobin ≥ 90 g/L; Total bilirubin≤1.5 upper limit of normal (ULN);Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST)≤2.5×ULN (ALT and AST≤5×ULN if liver metastasis); blood urea nitrogen (BUN) and Creatinine (Cr)≤1.5×ULN
  • Left ventricular ejection fraction (LVEF) ≥ 50% and QTc≤470 ms

Ki nem vehet részt

  • Patients who received Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine kinase inhibitors (TKI); II: Patients who received fulvestrant, everolimus or cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor
  • Patients unsuitable for endocrine therapy
  • Unable to swallow, chronic diarrhea and intestinal obstruction, there are many factors affecting drug use and absorption
  • Participated in other drug clinical trials within 4 weeks before admission
  • According to the judgement of the researchers, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of research (including, but not limited to, severe hypertension, severe diabetes, active infections, etc.)
  • Moderate infection occurs within 4 weeks before the first administration (e.g. intravenous drip of antibiotics, antifungal or antiviral drugs according to clinical criteria), fever(> 38.5 ℃) of unknown origin occurs during the screening period/before the first administration
  • Other malignant tumors, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma, have been diagnosed in the past five years
  • Active human immunodeficiency virus (HIV), hepatitis B or hepatitis C
  • Has suffered from any heart disease
  • Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial
  • Ib: Patients who had symptomatic brain metastasis; II: Patients who had brain metastasis
  • Researchers believe that patients are unsuitable for any other situation in this study

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The main purpose of this study was to evaluate the efficacy and safety of treatment with famitinib plus SHR6390 and endocrine therapy for hormone receptor (HR)-positive, Human Epidermal Growth Factor Receptor (HER) 2 - negative advanced breast cancer.

A vizsgálat csoportja

  • Treatment groupA vizsgált kezelés

    Famitinib Plus SHR6390 and Endocrine therapy

    Kezelés: Famitinib, SHR6390 és Fulvestrant

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Study to Evaluate the Efficacy and Safety of Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer
Publikációk
A regiszteradat frissítve
2024. december 17.